A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

BACKGROUND: WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-­escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF ( V600E)-mutant metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, Josep, Van Cutsem, Eric, Garralda, Elena, Tai, David, De Braud, Filippo, Geva, Ravit, van Bussel, Mark T J, Fiorella Dotti, Katia, Elez, Elena, de Miguel, María J, Litwiler, Kevin, Murphy, Danielle, Edwards, Michelle, Morris, Van Karlyle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020809/
https://www.ncbi.nlm.nih.gov/pubmed/36811382
http://dx.doi.org/10.1093/oncolo/oyad007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020809/
https://www.ncbi.nlm.nih.gov/pubmed/36811382
http://dx.doi.org/10.1093/oncolo/oyad007

Ejemplares similares